Prognostic value of GLIM criteria including systemic inflammation in patients with advanced cancer.

An assessment of systemic inflammation and nutritional status may form the basis of a framework to examine the prognostic value of cachexia in patients with advanced cancer. The objective of the study was to examine the prognostic value of GLIM criteria, including body mass index (BMI), weight loss (WL) and systemic inflammation (mGPS), in advanced cancer patients. Three criteria were examined in a combined cohort of patients with advanced cancer and their relationship with survival was examined using Cox regression methods. Data were available on 1303 patients. Considering BMI and the mGPS, the 3-month survival rate varied from 74% (BMI>28 kg/m) to 61% (BMI <20 kg/m) and from 84% (mGPS 0) to 60% (mGPS 2). Considering WL and the mGPS, the 3-month survival rate varied from 81% (WL ±2.4%) to 47% (WL≥15%) and from 93% (mGPS 0) to 60% (mGPS 2). Considering BMI/WL grade and mGPS, the 3-month survival rate varied from 86% (BMI/WL grade 0) to 59% (BMI/WL grade 4) and from 93% (mGPS 0) to 63% (mGPS 2). When these criteria were combined, they better predicted survival. On multivariate survival analysis, the most highly predictive factors were BMI/WL grade 3 (HR 1.454, P=0.004), BMI/WL grade 4 (HR 2.285, P<0.001) and mGPS 1 and 2 (HR 1.889, HR 2.545, all P < 0.001). In summary, a high BMI/WL grade and a high mGPS as outlined in the BMI/WL grade/mGPS framework were consistently associated with poorer survival of patients with advanced cancer. It can be readily incorporated into the routine assessment of patients.